All-in-One Vector Approach
Celyad Oncology focuses on using a single vector approach to generate CAR T-cells
Encoding multiple components of the construct, including the CAR, the cell selection marker (e.g. truncated CD19), therapeutic add-ons (e.g. cytokines), non-gene edited technology (e.g. short hairpin RNAs (shRNAs)) in a single vector helps Celyad Oncology to simplify the design and development of our CAR T-cell therapy candidates.
This single transduction, plug and play approach to CAR T-cell development also helps to streamline process development and manufacturing while broadening the potential applicability of our candidates.
